NCT06171789View on ClinicalTrials.gov

PRO1107 in Patients With Advanced Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

August 18, 2025

Study Completion Date

August 18, 2025

Conditions
Endometrial CancerOvarian CancerTriple Negative Breast CancerGastroEsophageal CancerNon-small Cell Lung CancerUrothelial Carcinoma
Interventions
DRUG

GEN1107

IV infusion of GEN1107

Trial Locations (7)

34236

Florida Cancer Specialists, Sarasota

37203

SCRI Oncology Partners, Nashville

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

START Mountain Cancer Center, Salt Lake City

85258

HonorHealth Research Institute, Scottsdale

410013

Institution of Hunan Cancer Hospital, Changsha

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY

NCT06171789 - PRO1107 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter